Prophylactic vs Therapeutic Anticoagulation in Hospitalized Patients With COVID-19

In patients hospitalized with COVID-19, in-hospital therapeutic anticoagulation with LMWH followed by edoxaban to day 42 did not statistically significantly reduce death and/or thromboembolic events compared with prophylactic anticoagulation followed by placebo.

Corresponding Authors: Mahir Karakas, MD, PhD, MBA, Department of Intensive Care Medicine, University Medical Center Hamburg, Martinistrasse 52, 20251 Hamburg, Germany (m.karakas@uke.de).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.